Interest in how exposure to excess nutrition affects disease precursor pathways in fetuses, neonates and infants has intensified in the past decade, owing to recognition that pregnant women with obesity and/or gestational diabetes mellitus (GDM) might transmit this phenotype to their offspring, leading to a vicious cycle of obesity and diabetes over generations. The 'Developmental Origins of Health and Disease' para digm posits that environmental exposures (in utero and dur ing early life) can permanently change the body's struc ture, physiology and metabolism, leading to increased disease risk and/or disease acceleration even after the exposure has occurred, including across gener ations 8, 9 . Evolutionarily, maternal transfer of excess nutrients might have contributed to increased survival chances for offspring; however, maternal obesity and diabetes mellitus are among the most powerful predictors of childhood obesity 10, 11 and other adverse health outcomes such as NAFLD, which affects up to 34% of children with obesity (5-19 years of age) 12 . A particularly alarming trend is the prevalence of obesity in children, affecting 8% of infants and toddlers (birth to 2 years of age) and 17% of children and adolescents (aged 2-19 years) in the USA 2 . With this high prevalence of obesity, NAFLD is predicted to become the most common aetiology for liver transplantation in the twentyfirst century 13 .
Compelling evidence suggests that the metabolic syn drome (which incorporates abdominal obesity, hyper tension, hyperglycaemia and dyslipidaemia) originates, in part, from a suboptimal intrauterine environment 9, 14, 15 . Data published in 2016 indicate that maternal obesity in humans promotes umbilical cord mesenchymal stem cells from newborn babies to preferentially differentiate into adipocytes rather than myocytes, correlating with an increase in neonate adiposity measured within 72 h of birth 16 . Furthermore, MRI and magnetic resonance spectroscopy in babies born to mothers with GDM who are obese showed a 70% increase in liver fat, with no stat istically significant increase in subcutaneous or intra abdominal fat 17 , suggesting that fetal exposures during gestation (that is, obesity, GDM or raised levels of fatty acids) increase NAFLD risk in the human neonate. In an MRI study in neonates born to mothers who were obese without GDM, intrahepatic fat was highly correlated with maternal BMI, but not birth weight 18 , suggesting mater nal obesity might be initiating events in the liver beyond increased adiposity in newborn babies.
As in adults, children with NAFLD can progress to cirrho sis and endstage liver disease 19 . Paediatric NASH (the more severe disease) has a multi dimensional aetio logy for which there is no approved therapy, often resulting in the need for liver transplantation. Potential approaches to treat established NAFLD include behav ioural changes, such as altering diet macronutrients and use of prebiotics and probiotics, and targeted approaches, including farnesoid Xactivated receptor (FXR; also known as bile acid receptor) and G proteincoupled bile acid receptor 1 (TGR5) agonists, endocannabinoid recep tor family antagonists, betaine (which acts as a methyl donor for epigenetic modifications), antioxidants and more recently inhibition of Hedgehog signalling compo nents (discussed later). Prevention or treatment in high risk mothers and their offspring might be warranted, given the increasingly younger age of onset and life time consequences of NAFLD in children and teens. Consequently, there is an enormous public health need to understand the underlying dietary or metabolic factors in mothers with obesity or GDM that lead to early obesity and NAFLD risk in the next generation. In this Review, we will discuss known gestational risk factors and early postnatal mechanisms for predisposition to NAFLD (and subsequent NASH) in human infants and animal models, with an emphasis on developmental programming, nutri tion, gut microbiota and changes in immunity affecting liver macrophages. We also present novel pathways that might be targets for future interventions.
Developmental programming of NAFLD Evidence in humans
Human studies have shown that maternal BMI predicts infant intrahepatocellular lipid storage and hepatic fat doubles over the first 10-12 weeks of age, regardless of breastfeeding 17, 18, 20 . In utero determinations of hepatic lipid content in human fetuses are limited by technical constraints; however, stillborn babies from mothers with GDM have an increased prevalence of histopathological hepatic steatosis 21 , supporting the development of pre natal steatosis. In addition to babies born to mothers with obesity or diabetes, neonates who are born with intrauterine growth restriction also have increased pre disposition to develop NAFLD postnatally 22, 23 . Although mech anisms underlying this pathophysiology are poorly understood, studies of stem cells from babies born to mothers with obesity have provided insight. These cells have increased adipogenic capacity 16 , and changes in amino acid and fatty acid oxidation metabolites in lipidexposed, adipocyte differentiated stem cells were predictive of rapid increases in adiposity from birth to 5 months of age 24 . Notably, biomarkers of mitochon drial dysfunction are elevated in plasma at 48 h of life in neonates born to mothers who are obese 25 .
Evidence in animal models
In rodents and nonhuman primates (NHPs), a maternal highfat diet, independent of maternal obesity, results in accumulation of triglycerides in fetal liver, hepatic oxid ative stress and apoptosis, priming the liver for later develop ment of NASH [26] [27] [28] [29] [30] . These Japanese macaque fetuses from mothers on a chronic highfat diet, regard less of obesity in the mother, have increased levels of hepatic triglycerides and oxidative stress, detectable in the early third trimester 28 . At 1 year of age, juven ile NHP offspring from this model have persistently increased liver triglycerides, increased expression of lipogenic genes in liver tissue and isolated hepatocytes, and increased activation of inflammatory gene expres sion in response to lipopolysaccharide (LPS) in hepatic macrophages 29 . Importantly, this liver phenotype per sists despite weaning to a healthy control diet, and is only present in offspring from mothers who developed obesity and insulin resistance on the highfat diet 29 .
Key points
• Exposure to maternal overnutrition or undernutrition increases susceptibility to NAFLD in childhood and hastens progression to NASH across the lifespan, especially when offspring are exposed postnatally to a high-fat (Western-style) diet • Maternal obesity and insulin resistance acting through the placenta produce intrauterine exposures including increased fetal insulin, lipids, inflammation and possibly hypoxia, which cause developmental programming of hepatosteatosis before birth • Programming of hepatic pathways including de novo lipogenesis, oxidative stress, mitochondrial dysfunction and inflammation persists in juvenile offspring born to and breastfed by mothers with obesity, despite weaning to a healthy diet • Pioneering microorganisms transmitted to the neonate at birth and microorganisms and bioactive milk products transferred during breastfeeding educate the infant immune system with lifelong implications for disease susceptibility • Pro-inflammatory and pro-remodelling phenotypes in liver macrophages might be programmed in infancy through alteration of intracellular metabolic and epigenetic pathways, increasing responsiveness to subsequent inflammatory stimuli • Supplements in preclinical models targeting novel pathways and receptors might be emerging therapies for use in tandem with a dietary shift to more complex carbohydrates during pregnancy
Multiple animal models demonstrate that continued exposure to a highfat diet during gestation and post natal life, compared with only postnatal highfat diet feeding, rapidly worsens the liver phenotype to fibro sis [31] [32] [33] . In mice, 3monthold offspring from mothers fed a highfat diet during pregnancy and lactation show increased hepatic steatosis and signs of NAFLD, which progresses to NASH when offspring are weaned onto a highfat diet [32] [33] [34] . Lactation also has an independent contribution towards the programming of NAFLD, as offspring born to controldietfed dams yet nursed by obese dams on highfat diet had increased hepatic Tnf and Il6 expression and levels of triglycerides 34 . In addi tion to these models of maternal overnutrition, mater nal undernutrition increases NAFLD predisposition in rodents with intrauterine growth restriction 35, 36 and post natal sheep whose mothers were nutrient restricted 37 . Collectively, these studies in humans, NHPs, rodents and sheep demonstrate that gestational under nutrition as well as overnutrition predisposes the offspring to NAFLD. Postnatal highfat diets, including during the weaning period, probably play an important part in disease acceler ation, but more research is needed to understand how breastfeeding and early regulation of the immune system and metabolism, as well as genetic factors, accelerate disease phenotypes.
Sexspecific effects might also contribute to the pro gramming of NAFLD. In humans, men have a higher rate of hepatic steatosis than women 38 . However, sex differences in offspring of obese pregnancies in animal models are less clear, with some studies showing increased liver triglyceride content in male offspring 
Intrauterine clues for NAFLD risk

Maternal insulin resistance
Maternal insulin resistance naturally occurs in preg nancy with advancing gestation. However, in pregnan cies complicated with diabetes, glucose delivery to the fetus increases, stimulating fetal insulin secretion. Increased fetal insulin concentrations in turn poten tiate fetal growth (a concept commonly referred to as the Pedersen hypothesis) and metabolic pathways regu lated by glucose and insulin 41 . Interestingly, fetal over growth and metabolic abnormalities are present even in mothers with diabetes who have good glycaemic control 42 . Furthermore, maternal obesity, independent of glycaemia, is highly correlated with fetal hyperinsulin aemia, growth and neonatal adiposity 43 . These studies suggest that fuels other than glucose (that is, lipids) in mothers with obesity contribute to excess fetal growth and developmental programming.
Excessive maternal insulin resistance owing to obe sity and/or poor diet is one important factor that might underlie in utero programming of fetal hepatic metabolic dysfunction and steatosis (FIG. 1) . Drivers associated with maternal insulin resistance might include excess fuel supply, inflammation, hormones (for example adipo nectin 44 ) and fetal hypoxia, as discussed later. In humans, increased maternal insulin resistance, independent of excessive gestational weight gain, mediates fetal adipo sity 45 , and increased maternal insulin resistance in mice results in progressive development of postnatal lipid deposition in the offspring 46 . Although insulin prod uced by the mother does not cross the placenta, exces sive insulin resistance during pregnancy might directly increase placental inflammation, altering nutrient trans fer to the fetus 47, 48 . In support of an early driving role for maternal insulin resistance, fetal hepatic steatosis was reduced when NHP mothers on a highfat diet were sup plemented with resveratrol, which improved maternal insulin sensitivity and placental function 49 .
The role of the placenta
The placenta might mediate the negative effects associ ated with maternal insulin resistance on the fetus and fetal liver. Placentas from humans with GDM and placentas from NHPs and rodent mothers with insu lin resistance have increased hypoxia, oxidative stress, cytokine production and inflammation [50] [51] [52] [53] , exposing the fetus to factors inducing lipogenic, inflammatory and mitochondrial oxidative stress pathways in the developing liver. In NHPs, placentas from mothers who develop obesity on a highfat diet have increased cytokine expression (including CCL2 (also known as MCP1) and IL1β), which could contribute to increased cytokine concen trations (including IL1β, IL2, IL4,  IL13, IL16, IL17, MCP1 and TNF) Figure 1 | Early in utero factors programming NAFLD. During pregnancy, mothers chronically consuming a high-fat or Western-style diet might be obese and insulin resistant, with increased plasma lipid and glucose levels that are transferred via the placenta to the fetus. Maternal insulin resistance and hyperinsulinaemia might additionally impair placenta function, reducing blood flow and decreasing fetal oxygen delivery, resulting in fetal hypoxia. Evidence also exists for increased inflammation and cytokine production in the placenta. Collectively, these exposures to the fetus comprise early factors that promote a pathological offspring phenotype. GDM, gestational diabetes; HFD, high-fat diet; ROS, reactive oxygen species; WSD, Western-style diet.
Placental lipid delivery to the fetus. By the third tri mester, most pregnant women have a blood lipid pro file that would be considered highly atherogenic in the non pregnant state 55 . This profile is characterized by a threefold increase in plasma triglyceride levels and a 25-50% increase in plasma total cholesterol concen tration 56 . In general, fetal cord and neonatal plasma lipid levels are much lower than those in adults 57, 58 . However, circulating triglyceride levels are higher in mothers with GDM or obesity 43 [63] [64] [65] . Thus, increased concentration and transport of lipids derived from the mother might be the source of lipids accumulating in the fetal liver.
Placental dysfunction and fetal hypoxia. The sever ity of liver damage in obesityrelated NAFLD in children and adults has been associated with concomi tant hypoxia and inflammation resulting from sleep apnoea 66 . Interestingly, fetal hypoxia owing to reduced utero placental blood flow and umbilical venous oxy genation is a common pregnancy complication in mothers with obesity or GDM. These fetuses also have increased plasma glucose and lactate concentrations, demonstrating metabolic adaptations in response to hypoxia 67 . Similar reductions in placental blood flow, placental vasculature, fetal oxygenation and neonatal survival have been found in NHP 50 and rat 68 models of maternal obesity.
Although the mechanisms for decreased placental function as a result of maternal obesity or GDM are not clear, term placentas from human pregnancies complicated by GDM have increased villus volume and villous immaturity, suggesting decreased transfer capacity 67, 69 . Trophoblast cells from GDM placentas also have decreased serotonin transport as a consequence of defective insulin signalling, which might be a mech anism contributing to decreased uteroplacental perfu sion and blood flow 70 . Further, in experimental animal models, in utero exposure to hypoxia and nutrient insufficiency increases susceptibility to hepatic steato sis, mitochondrial dysfunction, oxidative stress and NAFLD postnatally 35, [71] [72] [73] [74] [75] . These data strongly suggest that fetal hypoxia associated with placental dysfunction is an early clue that the heightened risk of NAFLD can begin in utero. Alternatively, fetal hepatic lipid accretion might result from a decrease, or a failed adaptive increase, in lipid oxid ation. In humans, progression from NAFLD to NASH is first associated with an adaptive increase in hepatic lipid oxidation 79, 80 . Over time, accelerated lipid oxidation is not sufficient to mitigate steatosis, which worsens, and NASH follows as oxidative stress and decreased mitochondrial oxidation develop 81 . In NHPs exposed to a highfat diet, cellular apoptosis is enhanced in the liver 30 . Hepatocyte apoptosis is now thought to have an important role in the progression to steatohepatitis in patients with NAFLD 82 . Further, an immature antioxidant defence system in the fetal liver compared with adults, combined with increased hepatic lipid load, might also contribute to elevated mitochondrial stress and apoptosis 83 .
Programmed mitochondrial metabolism
In addition to increased levels of hepatic triglycerides and apoptosis, the livers of mouse offspring from obese, highfatdietfed mothers have decreased electron trans port chain activity and increased expression of oxidative stress, fibrosis and inflammation genes 32, 33 , all signs of 'lipotoxicity' . Owing to increased lipid load and lack of an adaptive increase in mitochondrial oxidation, excess fatty acids in the fetus might not be completely oxidized, creating a backup of incomplete acylcoenzyme A species that can impair cell metabolism via increased cell stress, increased inflammation and decreased mitochon drial function and gene expression 84, 85 . In this context, excess free fatty acids combined with reduced mitochon drial metabolism could limit mitochondrial biogenesis. In fetal skeletal muscle from NHP mothers fed a high fat diet, we demonstrated reduced maximal mitochon drial respiratory capacity and increased oxidative stress in vitro and in vivo despite an upregulation in activity of electron transport chain components, suggesting these mitochondria are not capable of adapting to excess fuels 86 . Skeletal muscle mitochondria numbers in NHP fetuses are reduced 86 , and liver mitochondria numbers are suppressed in rat livers at weaning 87 and in mouse livers from adult offspring of mothers fed a highfat diet during pregnancy 32 . Mitochondrial DNA copy number was also reduced in liver samples from rat offspring of mothers fed a highfat diet and Ppargc1a mRNA, a regu lator of mitochondrial biogenesis, was decreased only in male offspring 88 . Interestingly, increased PPARGC1A promoter methylation and decreased mRNA expression of the gene was associated with decreased mitochon drial DNA content and increased insulin resistance in patients with NAFLD 89 . A major unanswered question is how fuel overload and/or hypoxia mechanistically programmes mitochondrial dysfunction, and whether mismatch between nuclear and mitochondrial genes has a role in mitochondrial damage and reduces the ability to oxidize fuels postnatally. Although correlations exist between excess circulating maternal lipid concentra tions, mitochondrial dysfunction and obesity in the off spring, there are no data in human infants, nor are early mechanisms for programming mitochondria before obesity development fully understood.
Epigenetic mechanisms programming NAFLD
Epigenetic mechanisms, including DNA methylation and histone modifications, also contribute to the program ming of NAFLD and have been reviewed elsewhere 90, 91 . However, the gene targets and causative epigenetic modifi cations leading to steatosis and fibrosis are not fully understood. Several studies have used largescale systems biology approaches 91 or genespecific approaches to identify epigenetic modifications that correlate with liver triglyceride accumulation 39, 40, 77, 89, 92 . In fetal liver from highfatdietfed NHP mothers, we observed decreased PGC1α acetylation 28 , which suggests increased PGC1α activity and expression of downstream genes for mitochondrial oxidative stress or control of fatty acid oxidation. In addition, histone H3 Lys14 acetylation (H3K14ac) is increased in fetal liver from highfat diet fed mothers, but this change is reversed when mothers are switched to a healthy diet 77 ; however, the genes regu lated by this modification remain unknown. In human pregnancies, increased PPARGC1A promoter methyl ation in umbilical cord samples taken at birth correlated with increased maternal BMI 93 , suggesting a potential programming mechanism for mitochondrial metab olism. Thus, the programming effects and potential epigenetic effects of maternal obesity on offspring mito chondrial function and metabolic control might not be organ specific, as they are evident in early embryogenesis and even in oocytes before fertilization 94, 95 .
Early postnatal factors Contribution of the gut microbiota A possible pathway linking maternal obesity and diabe tes with offspring NAFLD susceptibility is through the effects of maternal metabolic status on early microbial colonization of the offspring's gastrointestinal tract. Indeed, animal studies have demonstrated direct roles for the gut microbiota in each of the liver lesions that are observed in NAFLD, including steatosis 96 , NASH 97 and fibrosis 98 . However, mechanistic evidence showing early changes in liver or gut functions that precede disease manifestation is needed to understand causation (FIG. 2) . Emerging evidence suggests that the severity of NAFLD postnatally is strongly associated with gut dysbiosis 99 and a shift in gut metabolic function, including production and utilization of shortchain fatty acids (SCFAs) and bile acids [100] [101] [102] [103] . Figure 2 | Postnatal events contributing to steatosis and progression to NASH. Steatosis is present in the fetal liver in offspring from obese pregnancies and remains evident in the neonatal liver. Additional early insults after birth in these offspring include exposures from breast milk, microbiota, maturation of immune pathways, inflammation and impaired mitochondrial function. Each of these exposures furthers the progression of fatty liver disease. Across the lifespan, continued exposure to an unhealthy diet after weaning can represent a 'second hit' that accelerates the liver phenotype towards development of NASH.
Extensive research has shown that diet modulates the composition and function of gut microorganisms in humans and other mammals [105] [106] [107] [108] [109] . However, despite the rapid turnover of gut microbes in response to acute dietary changes, longterm dietary habits play a large part in determining gut microbiota composition 110, 111 . In the NHP model, a maternal highfat diet caused per sistent (beyond 1 year) intestinal dysbiosis that remained in the offspring even after offspring were weaned on to a healthy diet 112 . Data published in 2016 showed that highfat diet intake during the third trimester in human mothers was associated with a variation in the neonatal gut microbiota that persisted through 4-6 weeks of age, suggesting that maternal diet can structure the infant gut microbiota 113 . In addition to gut microbiota changes resulting from a maternal highfat diet, there are lasting effects on liver inflammation and steatosis in the NHP model 29 . Mice born to Westernstyledietfed breeders had immune dysregulation and increased disease sus ceptibility as well as a heightened colonic inflammatory response, including increased liver LPS levels 114 . Taken together, these observations suggest that maternal diet driven changes in the offspring gut microbiota can have persistent effects on the host immune system that increase risk for inflammatory diseases in later life.
Alteration of the infant gut microbiota
Although the maternal gut microbiota differs between women who are overweight and those of a normal weight 115, 116 , and differences in the gut microbiota exist in 6monthold infants who later became overweight at 7 years of age compared with infants who did not later become overweight 117 , whether the gut microbiota in early life establishes obesity remains to be determined. In addition to maternal obesity and diet, the coloniza tion of the infant gut is also powerfully affected by mode of delivery (Caesarean section versus vaginal delivery), antibiotic use and breastfeeding exposure 118 . An increasing body of epidemiological and animal stud ies links changes in the infant gut microbiota to allergy, autoimmune disease and obesity risk later in life [118] [119] [120] , suggesting that the early neonatal immune system is pro grammed; however, pathways between specific microbes and their functions remain elusive. The earliest coloniz ing species are recognized as 'pioneering microbes' that educate the developing immune system from a state of hyperstimulation to one of immune tolerance. Both Bacteroides and Lactobacillus, abundances of which are reduced by maternal obesity, are capable of inhibiting the NFκB pathway, which could affect inflammatory states in the mother and her offspring, particularly if the off spring inherits this altered microbiota 121 . Maternal gut dysbiosis and its accompanying systemic inflammation, if transmitted to the newborn baby, can be reasonably hypothesized to alter the establishment of the nascent infant immune system.
Breastfeeding signals and effects of obesity
Maternal breast milk promotes the colonization and development of the intestinal microbiota in the infant. Breast milk bacterial composition varies by lactation stage 122 , gestational age 122 , maternal health status 123 and mode of delivery 122, 123 . Human breast milk contains a lowbiomass microbiota that has been previously hypothesized to be partially derived from the mater nal gut 124, 125 . The most abundant genera in the breast milk microbiota are Streptococcus, Staphylococcus, Serratia and Corynebacterium 125 . Bifidobacterium and Lactobacillus spp. are also found in breast milk and are transferred to the neonatal gut 126, 127 . In addition to bacteria, breast milk contains high levels (the third largest component of human milk) of human milk oligosacchar ides, comprising complex sugars with sub stantial pre biotic effects that serve as a source of energy for desired microbial growth 128, 129 . Thus, breastfeeding provides prebiotics, in the form of oligosaccharides, and probiotics, in the form of live bacteria that contribute to the colonization of bacteria in the infant gut. Formula fed infants are not exposed to the same nutrients that breastfed infants are and thus develop a different microbiota 130 . The breakdown products of human milk oligo saccharides support the growth of the commensal microbiota and promote antiinflammatory effects, and represent a crucial window of opportunity for shaping the infant gastrointestinal and immune systems as well as the adult gut microbiota 131 .
In newborn babies and in mice, the immune system gains tolerance to microorganisms based on the timing of colonization. Gammaproteobacteria are a major source of LPS and are considered transient pioneering bacteria important for developing endotoxin tolerance and pro tection against excessive inflammatory and autoimmune gastrointestinal disorders later in life [132] [133] [134] . A statistically significant 50% reduction in Gammaproteobacteria abundance was found in stool of 2weekold babies born to mothers with obesity, along with increased levels of acetate 135 , which promotes hepatic de novo lipogenesis and NAFLD. We have transferred gut microbes from infants born to mothers who are obese into germfree mice; these mice showed signs of elevated cytokines in portal blood and liver endoplasmic reticulum stress (increased gene expression of spliced Xbp1) when com pared with mice colonized with stool from babies born to mothers of a normal weight (J. E. Friedman, unpublished work). Chronic endoplasmic reticulum stress is associ ated with hepatic steatosis, insulin resistance, oxidative stress and hepatocyte cell death 136, 137 , and is present in the livers of patients with NAFLD or NASH 138, 139 . Although more work needs to be done, these data suggest that alterations in the neonatal microbiota born to mothers with obesity might produce an early proinflammatory response, resulting in altered liver gene expression and, potentially, persistent immunological changes in the infant. Longitudinally detailed analyses at the strain level are necessary to understand these effects on metabolic reprogramming of the immune system and susceptibility to liver disease in later life.
Bile acids as early programming events for NAFLD
The gut microbiota is essential for the metabolism of primary bile acids into secondary bile acids, yet only in the past few years has this process been considered in NAFLD pathogenesis. In contrast to the toxic effects of excess accumulation of bile acids on hepatocytes, certain hydrophilic, less toxic bile acids such as urso deoxycholic acid have antiinflammatory effects that might be relevant for NAFLD 140 . Bile acids function as signalling molecules through a variety of receptors to regulate their own synthesis as well as other metabolic processes, such as glucose, lipid and energy homeo stasis, as reviewed elsewhere 140 . In the case of NAFLD and NASH, bileacidrelated pathways might be involved given that the microbiota, through defined enzymatic activities (including deconjugation, dehydroxylation and oxidation, among others), is a critical modulator of bile acid pool size and composition and can substan tially modify the chemical and signalling properties of bile acids 100, 102, 141 . On the other hand, bile acids also shape the intestinal microbiota through direct anti microbial effects 142 . Further, the action of bile acids via the hepato cyte FXR and Kupffer cell TGR5 receptors have been demonstrated to inhibit lipid accumulation and inflammation, respectively [143] [144] [145] . The transplant ation of dysbiotic mouse microbiota into germfree mice resulted in increased hepatic fat accumulation through SREBP and CREB, regulators of de novo lipogenesis, and eleva ted hepatic inflammation, such as NFκB activity; these pathways are known to be inhibited by FXR and TGR5 activation [146] [147] [148] . A key question is whether the mechanism by which the gut microbiota influences liver fat includes modulation of bile acid metabolism 149 . Compelling human and animal data suggests that in utero exposure to excess bile acids during pregnancy results in reprogramming of metabolism and increased risk of the metabolic syndrome in later life 150 . Gut microbes can also affect bile acid pool composition 151 , by conjugating and deconjugating bile acids. Thus, physiological bile acid pool compositions might have homeostatic antiinflammatory affects, altered in the setting of a dysbiotic intestine, and might exert effects that promote macrophage activation 147, 152, 153 (FIG. 3) .
Several important questions are raised pertaining to both the fundamental biological significance and poten tial clinical relevance of these results. Are there changes in early infant intestinal microbes that result in metabolic programming across the immune system? Given that the early infant microbiota is unstable and matures over the first 1-2 years of life 154, 155 , would longer breastfeed ing (encouraged in all infants) promote a healthier liver and changes in bile acid composition? Work to date has mostly focused on bacterial taxonomic composition of these communities rather than on the functional features they express. Clearly, wellcontrolled longitudinal studies are critically important to understanding how the early changes in the gut microbiota seed the development of NAFLD in the infant of a mother with obesity. Figure 3 | Early liver microenvironment influences macrophage programming. The prenatal and perinatal liver microenvironment in the offspring of mothers with obesity promotes programming of liver macrophages (recruited and resident) via metabolic and epigenetic alterations, favouring a profibrotic phenotype and expression of proinflammatory molecules upon a second postnatal 'hit'. This maladaptive immunity might directly result from alterations in the infant gut-liver axis associated with dysbiosis owing to perinatal colonization of the infant intestine with microbiota from a mother with obesity, and postnatal compromise of the intestinal barrier leading to altered absorption of endotoxins, cytokines, bile acids, SCFAs, metabolites and hormones. Disturbances in macrophage function can lead to aberrant tissue repair, such that uncontrolled production of inflammatory mediators and growth factors, deficient generation of anti-inflammatory macrophages or failed communication between macrophages and stellate cells contributes to persistent liver injury and the development of pathological fibrosis. Arg1, arginase 1; FGF19, fibroblast growth factor 19 (also known as FGF15 in mice); FSP1, fibroblast-specific protein 1 (also known as S100-A4); FXR, farnesoid X receptor (also known as bile acid receptor); HIF1, hypoxia-inducible factor 1; MMP, matrix metalloproteinase; SCFA, short-chain fatty acid; TGFβ, transforming growth factor β; TGR5, G protein-coupled bile acid receptor 1; TIMP, tissue inhibitor of matrix metalloproteinase (also known as Metalloproteinase inhibitor 1); TLR, Toll-like receptor.
Hepatic macrophages and NAFLD
Concept of the gut-liver axis
Intestinal permeability is increased in children with NAFLD and correlates with more severe liver disease 156 . In newborn babies, permeability of the gut during neo natal life is also increased 157 , allowing uptake of nutri ents and development of systemic immune tolerance. However, a shift in microbial colonization, in addition to altering inflammatory stimuli, can expose the neo nate liver to harmful microbial products and metabo lites that interact with the innate and adaptive immune systems 158, 159 . Owing to its direct anatomical connection to the gut via the portal vein, the liver is exposed to the entire gamut of gutmicrobederived factors (for exam ple endotoxins), gutderived mediators such as cytokines (including IL1β and TNF) and hormones (fibroblast growth factors), primary and secondary bile acids, and metabolites (derived from both host and microbiota, for example citrulline, SCFAs, bile acids, succinate and lactate) (FIG. 3) . Liver macrophages are the first line of defence and have a homeostatic role 160 , protecting the host [161] [162] [163] [164] and critically contributing to initiation 165 and resolution 165 of liver injury from pathophysiologi cal alterations in the gut [165] [166] [167] [168] [169] [170] [171] [172] . The intricate functional relation ships between the liver, its macro phages and the gut have been conceptualized as the gut-liver axis [173] [174] [175] . The importance of the gut-liver axis in liver pathol ogy has been substantiated by a host of studies implicat ing gutderived factors (for example bacterialderived endotoxins) as mediators of the pathogenesis of liver injury, including NASH 100, [176] [177] [178] [179] [180] [181] [182] [183] . Gutderived factors are thought to enter the portal vein in increased concentra tions because of increased gut permeability, secondary to dysbiosis. Endotoxinactivated liver macrophages then produce proinflammatory cytokines that promote liver inflammation (including IL1β, TNF and IL6) 181 . A role for the gut-liver axis is not unique to the patho genesis of NAFLD or NASH; it also has been demon strated to contribute to the pathogenesis of cholestatic liver disease associated with total parenteral nutrition 181 . In addition, various mouse models of liver fibrosis have demonstrated the involvement of increased gut perme ability, absorption of gutderived endotoxins and hepatic macro phage activation in its pathogenesis [176] [177] [178] [184] [185] [186] . In addition to governing endotoxin tolerance in neo nates, studies have identified that increased concen trations of gutderived LPS are necessary for activating macrophages in mouse models of cholestasis, induced by parenteral nutrition with intestinal injury or fibro sis secondary to bileduct ligation 180, 181 . Abrogation of TLR4 signalling or suppression of intestinal microbiota with antibiotics was protective against both macro phage activ ation and liver injury in these models 180, 181 . Similarly, there is evidence that the pathogenesis of NAFLD and NASH involves activation of hepatic macro phages 187 that might begin with in utero exposures to lipid over load or fetal hypoxia as one critical pathway, and poten tially by gutderived or metabolic factors other than fat, such as succinate 159 or SCFAs 188 , as another crit ical pathway (FIG. 3) . However, considering that alterations in the gut-liver axis alone might be necessary but not sufficient to promote NASH, it will be critical to iden tify extraintestinal factors and pathways that advance the disease.
Macrophages and tissue homeostasis
How direct interactions between macrophages and local cells, such as stellate cells and fibroblasts, con trol the pathogenesis of NASH, or how they maintain tissue homeostasis, is an active area of investigation 189 . Furthermore, the relative contributions of transcription factor expression, macrophage ontogeny and the hepatic microenvironment to macrophage programming and function in the regulation of liver homeostasis and in the pathogenesis of NAFLD and/or NASH remain to be determined. To minimize damage to inappropriate tar gets and preserve tissuespecific functions, the timing and magnitude of macrophage responses must be coordin ated 160 . Macrophages have also been recognized as crit ical in promoting resolution when the injury subsides or has been cleared 165 . Crosstalk between macrophages and other tissue cells regulates immune responses, from initial inflammatory activ ation to res olution and finally tissue repair 160, 161, 190 . Major unanswered ques tions include which mechanisms operate in liver macro phages to maintain homeostasis in the face of high micro environment variability, and which mechanisms antagonize and overturn tissue homeostasis such that liver macrophages become activated or programmed to promote nonresolving and profibrotic liver injury 191, 192 .
Metabolic reprogramming of macrophages
Macrophage programming involves increased expres sion of arginase 1, downstream of hypoxiainducible factor 1 (HIF1), and metabolic reprogramming to favour aerobic glycolysis in sterile chronic inflammatory con ditions 190, 193 . Mechanistic studies have demonstrated that macrophages can retain immuno logic memory (referred to as trained immunity), a phenomenon that involves HIF1dependent metabolic pathways and a shift to aerobic glycolysis (a prerequisite for macrophage pro inflammatory activation) and epigenetic reprogram ming [194] [195] [196] . These changes lead to the promotion of transcriptional programmes that alter intracellular sig nalling and metabolic pathways (for example, increased glycolysis and reprogramming of the tricarboxylic acid cycle) 190, 194, 197 . Some of the earliest evidence that macro phages might exhibit memorylike features came from investigations of LPSinduced tolerance. In one such study, genespecific chromatin modifications were associ ated with silencing of genes coding for inflam matory molecules in response to LPS stimulation, and the priming of other genes coding for antimicrobial molecules 198 . These findings suggested that macrophage polarization and activation in response to subsequent activation signals could be primed by LPS 190, 199 . Given the early gut permeability engendered by dys biotic infant gut microbiota, it is tempting to speculate that certain bacteria and their outputs might trigger programming events in liver macrophages and in progenitor cells in the bone marrow as well. Indeed, evidence has emerged to indicate that innate immune memory can be transferred via haematopoietic stem and progenitor cells that alter the function of their differentiated progeny 200 , depend ing upon the composition of the gut micro biota 201 . Furthermore, in utero exposures in mothers with obe sity, such as fetal hypoxia (FIG. 1) , might initi ate macro phage epigenetic reprogramming. Whether liver macrophage responses have the cap acity to be primed or reprogrammed by the microbiota in babies born to mothers with obesity, or whether the baseline microbes have a role in the future health of the offspring by exert ing a newly described type of immunological memory upon further insult, remains to be determined.
Resident and recruited macrophages
Under inflammatory conditions, bonemarrowderived monocytes are recruited to the liver, where they differ entiate into macrophages and are critical for initiation and resolution of liver injury and inflammation 165, 166 . Recruited macrophages are potentially functionally distinct from resident macrophages and probably dis play different phenotypes in early (proinflammatory) versus late (proresolving) stages of inflammation 165 . A limitation to most studies of macrophage immuno metabolism is that resident and recruited macrophages are assessed as a uniform population rather than separ ately. Accordingly, functional dichotomy in resident versus recruited macrophages at different stages of inflammation might be directly linked to program ming of cellular metabolism 190, 202, 203 . Resolving the role of tissue macrophage ontogeny, in terms of the relative contributions of yolksacderived, fetalliverderived and bonemarrowderived macrophages to the pool of tissue resident and recruited macrophages, might contribute to better understanding of the mechanisms that control tissue injury in NASH [204] [205] [206] . Additionally, it remains to be determined if and how longlasting functional changes (trained immunity, innate immune memory and epigenetic changes) in recruited and/or resident macrophage populations occur, and if and how these cells have a role in promoting nonresolving chronic inflammation. A study published in 2016 has shown that activation of TLR4 by microenvironmental cues stimu lates divergent signalling pathways in macrophages 207 , suggesting that crosstalk with microorganisms might be functionally relevant for controlling matrix formation and tissue injury.
Macrophage reprogramming before obesity
In addition to being exposed to maternal-placental factors, the prenatal and perinatal liver microenviron ment receives signals from the gut microbiota that can affect hepatic macrophage metabolic reprogramming. Dysbiosis has been shown to compromise the intes tinal barrier, setting the stage for a pathophysiological gut-liver axis and for programming and activation of liver macrophages towards a profibrotic phenotype 181, 183 . Gut microbiota dysbiosis can increase concentrations of proinflammatory cytokines, metabolites (such as succin ate and lactate), bile acids and levels of endo toxins in the portal vein, all of which might affect hepatic macr ophage activation 152, 181, 208, 209 . These alterations could promote pathways that induce lasting changes in the epigenetic landscape of the macrophage, priming a pro inflammatory and profibrotic phenotype upon exposure to a second insult, such as a Westernstyle diet (FIG. 3) . This profibrotic macrophage phenotype in chronically inflamed and fibrotic tissue can occur in the relative absence of microbes and can be considered a sterile inflammatory pathology 193 . Considering that the fetal liver has a prominent role as a haematopoietic organ and in fetal macrophage development, and considering the possibility that macro phages in various tissues could be fetalliver derived, prenatal alterations in the liver microenvironment might not only affect programming of liverresident macro phages but also macrophages in other tissues, includ ing adipose tissue and bone marrow 204, 205 . Unlike adult tissues, fetal tissues have a high capacity to heal with out scarring or fibrosis 210 . Whether exposure of liver macrophages prenatally to maternalderived factors or perinatally to infant gutderived factors interferes with physiological programming of the tissue such that it aberrantly assumes an adult phenotype and promotes scarring and fibrosis is unclear. Given the severity and rapid progression of paediatric liver disease upon diag nosis 5 , future studies are required to identify the early microenvironmental features that programme liver macrophages, activate specific phenotypes conducive to chronic inflammation, or prevent resolution and pro mote continuous activation of proremodelling and/or profibrotic pathways that contribute to progression of fatty liver disease.
Targeting the gut-liver axis
Modulating maternal macronutrients
Intervention strategies designed to ameliorate the devel opmental programming of NAFLD are primarily pre clinical; however, clinical interventions have targeted childhood obesity by modulating macronutrients or using drugs or supplements (TABLE 1) . Few effective diet ary interventions have been identified, which is concern ing as early intervention has been shown to have a crucial effect on laterlife health and well being of offspring 211 . Studies using the anti diabetic drug metformin, provided to mothers with obesity throughout pregnancy, did not find an effect on neonate birth weights [212] [213] [214] . At 2 years of age, offspring of mothers with GDM exposed in utero to metformin had increased subcutaneous fat as compared with insulinexposed counterparts, although overall body fat was the same 215 . Longerterm followups will be required to determine whether children receiving met formin treatment in utero develop less visceral fat and, potentially, increased insulin sensitivity. Previous evi dence suggests that dietbased interventions are effec tive in achieving a reduction in gestational weight gain in pregnant women with GDM who are overweight or obese, but result in no substantial effect on birth weight, as reviewed elsewhere 216, 217 . However, a promising approach in women with GDM is the use of a diet higher in com plex carbohydrates and lower in fats; a study in pregnant women with GDM showed improved maternal and infant outcomes after only 7 weeks of treatment 218, 219 .
Thus, it is likely that a combin ation of a healthier diet and nutritional or pharmaco logical supplements will be required to achieve benefits in mother and offspring, taking the GDM status of the mother into account.
Altering the gut microbiota
As reviewed elsewhere by Patterson et al. 220 , diet is a key modulator of the gut microbiota. NAFLD inci dence and disease severity have been linked to gut dys biosis in a wellcharacterized population of adults with NAFLD, with Bacteriodetes abundance independently associated with progression to NASH and Ruminococcus linked to fibrotic lesions 98 . Comparison between humans who are lean or obese shows that bacterial species diversity is reduced in obesity 221, 222 ; mucindegrading bacteria Akkermansia muciniphila and antiinflammatory Faecalibacterium prausnitzii are emerging as potential key therapeutic targets 223 , although the mechanisms govern ing their role in inflammationdriven metabolic disease are yet to be determined. Probiotics and prebiotics have been investig ated in both clinical (TABLE 1) and preclin ical models; however, as we have reviewed elsewhere 118 , most probiotic trials administered during pregnancy have had limited success in improving maternal and neo natal outcomes. The probiotic Lactobacillus rhamnosus GG, administered in conjunction with Bifidobacterium lactis, has been most commonly studied in pregnancy. Shortterm prenatal treatment in women without obesity seemed to affect development of the fetal innate immune system 224 , whereas longer perinatal treatment did not affect infant birth weight 225 . Interestingly, the probiotic intervention reduced weight gain in the offspring dur ing the first 24 months of life; however, by 4 years of age the intervention was not protective 226 , suggesting thera peutic interventions might need to be implemented in multi ple time windows throughout development to blunt NAFLD pathogenesis.
Few studies have investigated efficacy of probiotics in paediatric patients. Nonetheless, targets for probiotic therapies in adults have been identified. For example, butyrateproducing bacteria such as Roseburia intestin alis, Eubacterium hallii and Faecalibacterium spp. have been implicated in reducing insulin resistance in humans 227 . In a preclinical model of NAFLD in rats, periodic treatment beginning postnatally with a pro biotic mixture including Bifidobacterium, Lactobacillus, Lactococcus and Propionibacterium was protective against weight gain, improved insulin sensitivity and prevented development of NAFLD in adult animals 228 , suggest ing these genera include candidates for future prenatal testing. Pyrroloquinoline quinone (PQQ), a bacterial cofactor important in reproductive health, might have probiotic properties. Engineered PQQsecreting E. coli str. Nissle protected against hepatic hyperlipidaemia in a rat model of ethanolinduced liver damage 229 , support ing PQQ as a potential novel strategy to reduce risk of NAFLD development. The key to optimizing probiotic or prebiotic approaches are functional maps of both healthy and obese gut microbiota, particularly for infants, which are only just being investigated 230 .
Targeting bile acids
Bile acids and their receptors have emerged as potent therapeutic targets in NAFLD. The safety and efficacy of obeticholic acid, a synthetic bile acid analogue and FXR agonist, has been investigated in several adult human studies for treatment of both NAFLD 231 and NASH 232 with promising yet mixed results, and clinical trials in adults with other FXR agonists are currently underway 233 . INT767, a powerful dual FXR and TGR5 agonist, exerted an antiinflammatory response and improved NAFLD in an obese db/db mouse model 152 ; the drug has now entered phase I clinical studies in healthy human volunteers. Evidence from a human study com paring the post prandial bile acid profiles of patients with NASH and healthy individ uals suggests that bile acid hydrophobicity is implicated in progression of hepatic inflammatory disease 234 and bacterial processing of bile acids might be a potential avenue for therapeutic inter vention. Additionally, bile acids are cosecreted with phosphatidylcholine, and the choline supply is critically important for both prenatal and postnatal development 235 . Supplementing sows during gestation with betaine, a cho line derivative, suppressed expression of lipogenic genes in neonatal piglet livers 236 . Taken together, modifying the abundance, composition, processing and secretion of bile acids has shown efficacy in ameliorating hepatic fat accre tion, at least in pre clinical models, and these pathways represent promising candidates for preclinical testing.
Targeting Hedgehog signalling
An emerging understanding of the role of the Hedgehog signalling pathway in the pathogenesis of NAFLD and NASH has led to preclinical and clinical trials of pathway mediators. Hedgehog signalling is inhibited in healthy liver but activated in disease; ballooned hepatocytes prod uce the Hedgehog ligand sonic hedgehog, which stimulates hepatic stellate cells and fibroblasts, initiating a profibrotic response 237 . Inhibiting or eliminating smooth ened, a G proteincoupled receptor mediating signalling in the presence of sonic hedgehog ligand 238 , resulted in reduced macrophage activation and expression of proinflammatory genes in a mouse model 239 . Analysis of liver biopsies from patients with NASH enrolled in the PIVENS trial showed that response to treatment (vitamin E) was inversely associated with levels of sonic hedgehog 240 . Prenatal supplementation with vitamin E has not been studied in the context of NAFLD; however, it has not been associated with positive outcomes in other inflammatory models such as allergy 241, 242 . Other medi ators of Hedgehog signalling, including natural prod ucts such as isoflavones, might have more therapeutic promise, as reviewed elsewhere 243 .
Alternative approaches
Antioxidants and bioactive lipids have been proposed as potential treatments for NAFLD and NASH but many have not yet been studied in human pregnancy. Perinatal and postnatal human studies have investig ated the effect of treatment with fish oil and ω3 poly unsaturated fatty acids on various aspects of offspring health and develop ment. Fish oil and fatty acid supple ments during peri natal or postnatal periods have not been effective at reducing offspring BMI or fat mass (TABLE 1) , although fish and cod liver oil consumption during pregnancy was correlated with higher maternal and offspring docosahexanoic acid levels and increased placental weight 244 . Treatment with fish and cod liver oil during the first year of life reduced subsequent risk of type 1 diabetes mellitus 245 and eczema 246 , presumably via the anti inflammatory action of docosahexanoic acid and similar longchain ω3 fatty acids. Our lab oratory has used a Fat1 transgenic mouse model (which can endogen ously convert ω6 fatty acids to ω3 fatty acids) to test the effect of increasing the maternal ω3 to ω6 tissue fatty acid ratio during highfat diet consump tion. Wildtype offspring of Fat1 dams had decreased hepatic lipid accumulation and were protected from highfat dietinduced inflammation 27 . Thus, increasing the maternal ω3 to ω6 fatty acid ratio and reducing placental inflammation might be a promising target for improving outcomes in the fetus of a mother with obesity consuming a highfat diet.
Other antioxidants have shown efficacy for reducing steatosis in adult human or animal studies and might be potential pathways to target in pregnancy models. Silibinin (also known as silybin) is a potent antioxidant extracted from milk thistle. When coformulated with phosphatidylcholine and vitamin E, treatment of adult patients with NAFLD with silybin improved insulin resistance, liver histology 247 and indices of hepatic and metabolic function 248 . In support of antioxidant therapy, restoration of antioxidant balance with vitamin A, E, and C and selenium supplementation during Western style diet feeding in pregnant rats was associated with decreased inflammation and oxidative stress in the preimplantation embryo, fetus and neonate 249 . Shortterm resveratrol trials in adult humans with NAFLD have resulted in improved measures of hepatic insulin sensitivity and reduction of inflammatory mediators, although fat accretion was not altered 250 . A study published in 2016 by Vega et al. 251 demonstrated reductions in body fat and serum triglyceride levels in adult offspring of proteinrestricted dams treated with resveratrol, although hepatic triglyceride concentration was not measured. Our group has previously shown a decrease in fetal hepatic triglyceride levels following maternal supplementation with resveratrol in obese NHPs 49 . Whether the beneficial effects of resveratrol on the fetal liver are direct, or indirect via improve ments in the maternal-placental-fetal axis, remains to be determined (FIG. 1) 49, 252, 253 . Resveratrol has also been demonstrated to act in the brain through the endocannabinoid system 254 . Endocannabinoids have emerged as versatile signal ling molecules mediating critical functions in almost every peripheral organ (reviewed elsewhere [255] [256] [257] ). Endocannabinoids and their bioactive oxidative prod ucts bind to the cannabinoid receptors, CB1 and CB2, as well as to peroxisome proliferatoractivated recep tors (PPARs) 258, 259 . Similar to bile acids, endocannabin oids symbiotically interact with the gut microbiota 260 . In animal models, hepatic CB1 activation results in fatty liver, hyperinsulinaemia, increased endoplasmic reticu lum stress and suppression of insulin signalling [261] [262] [263] . CB2 activation has been implicated in protection from liver fibrosis [264] [265] [266] [267] , fatty liver disease 268 and acute ischae mic liver injury 269, 270 . Although eliciting promising meta bolic results, human clinical trials with globally acting CB1 antagonists have had deleterious central effects 255 ; therefore, increased understanding of the systemic role of endocannabinoid signalling in metabolic disease will be required before modulation of this system can be used during pregnancy.
Conclusions NAFLD affects >34% of children with obesity 12 ; however, the factors that accelerate disease progression to fibro sis, cirrhosis and liver failure are multifactorial. With almost twothirds of all women in the USA entering pregnancy overweight or obese, and the increased inci dence of GDM and other environ mental exposures and stressors present, the majority of fetuses are subjected to some form of metabolic or environmental exposure and insult, with detrimental effects on their future health. However, the mechanisms underpinning the link between exposure to an adverse in utero environ ment and metabolic disease in later life remain largely unknown. Moreover, the parameters currently used to assess in utero meta bolic exposure, including maternal weight gain and infant birth weight, are poor predictors of later metabolic disease, suggesting that programming probably involves subtle effects on organs and tissues during development beyond birth weight. Thus, there is an urgent need to identify early maternal and infant bioenergetic, epi genetic, inflammatory and microbial biomarkers that mark mechanisms underlying meta bolic disease in the next generation. Greater emphasis on prevention in highrisk infants could 
